Clinical data in 11 CML patients treated with IFN-
| Patient No. . | Sex/Age at Diagnosis . | Sokal's Score . | Karyotype at Presentation [% Ph+] . | Treatment . | Duration of Follow-Up (mos) . | Duration of CCR (mos) . |
|---|---|---|---|---|---|---|
| 1 | M/27 | 0.83 | t(9;22)(q34;q11) [100%] | HU, IFN-α2a, Ara-c | 150 | 120 |
| 2 | M/46 | 0.61 | t(9;22)(q34;q11) [100%] | HU, BU, IFN-α2a, Ara-c | 183 | 108 |
| 3 | M/68 | 0.79 | t(9;22)(q34;q11) [91%] | HU, IFN-α2b, Ara-c | 51 | 36 |
| 4 | M/70 | 0.83 | t(9;22)(q34;q11) [94%] | HU, IFN-α2b, Ara-c | 127 | 36 |
| 5 | F/53 | 0.72 | t(1;9;22)(q41;q34;q11) [95%] | HU, IFN-α2a, Ara-c | 144 | 12 |
| 6 | F/43 | 0.83 | t(9;22)(q34;q11) [100%] | HU, BU, IFN-α2a | 146 | 72 |
| 7 | M/56 | 0.71 | t(9;13;22)(q34;q12;q11) [74%] | HU, IFN-α2b | 57 | 36 |
| 8 | M/52 | 0.82 | t(2;9;22)(p13;q34;q11) [12%] | HU, IFN-α2b | 59 | 36 |
| 9 | F/35 | 0.61 | t(9;22)(q34;q11) [100%] | HU, BU, IFN-α2a | 170 | 36 |
| 10 | F/57 | 1.5 | t(9;11;18;22)(q34;q13;p11;q11) [100%] | HU, IFN-α2b | 47 | 24 |
| 11 | M/60 | 0.79 | t(9;22)(q34;q11) [17%] | HU, IFN-α2b, Ara-c | 41 | 36 |
| Patient No. . | Sex/Age at Diagnosis . | Sokal's Score . | Karyotype at Presentation [% Ph+] . | Treatment . | Duration of Follow-Up (mos) . | Duration of CCR (mos) . |
|---|---|---|---|---|---|---|
| 1 | M/27 | 0.83 | t(9;22)(q34;q11) [100%] | HU, IFN-α2a, Ara-c | 150 | 120 |
| 2 | M/46 | 0.61 | t(9;22)(q34;q11) [100%] | HU, BU, IFN-α2a, Ara-c | 183 | 108 |
| 3 | M/68 | 0.79 | t(9;22)(q34;q11) [91%] | HU, IFN-α2b, Ara-c | 51 | 36 |
| 4 | M/70 | 0.83 | t(9;22)(q34;q11) [94%] | HU, IFN-α2b, Ara-c | 127 | 36 |
| 5 | F/53 | 0.72 | t(1;9;22)(q41;q34;q11) [95%] | HU, IFN-α2a, Ara-c | 144 | 12 |
| 6 | F/43 | 0.83 | t(9;22)(q34;q11) [100%] | HU, BU, IFN-α2a | 146 | 72 |
| 7 | M/56 | 0.71 | t(9;13;22)(q34;q12;q11) [74%] | HU, IFN-α2b | 57 | 36 |
| 8 | M/52 | 0.82 | t(2;9;22)(p13;q34;q11) [12%] | HU, IFN-α2b | 59 | 36 |
| 9 | F/35 | 0.61 | t(9;22)(q34;q11) [100%] | HU, BU, IFN-α2a | 170 | 36 |
| 10 | F/57 | 1.5 | t(9;11;18;22)(q34;q13;p11;q11) [100%] | HU, IFN-α2b | 47 | 24 |
| 11 | M/60 | 0.79 | t(9;22)(q34;q11) [17%] | HU, IFN-α2b, Ara-c | 41 | 36 |
CML indicates chronic myeloid leukemia; HU, hydroxyurea; BU, busulfan; IFN, interferon; Ara-c, cytosine arabinoside; CCR, complete cytogenetic remission.